Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

Tesch, Hans; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M.; Marme, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A.; Lux, Michael P.; Lueftner, Diana; Hadji, Peyman; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Taran, Florin-Andrei

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial

Author:

Tesch, Hans; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M.; Marme, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A.; Lux, Michael P.; Lueftner, Diana; Hadji, Peyman; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Taran, Florin-Andrei

Tübinger Autor(en):

Ţăran, Florin-Andrei

Published in:

International Journal of Cancer (2019), Bd. 144, H. 4, S. 877-885

Verlagsangabe:

Wiley

Language:

English

Full text:

http://dx.doi.org/10.1002/ijc.31738

ISSN:

1097-0215